TrapEase vena cava filter: Experience in 751 patients

Sanjeeva P. Kalva, Stephan Wicky, Arthur C. Waltman, Christos A. Athanasoulis

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Purpose: To evaluate the clinical safety and efficacy of the TrapEase vena cava filter in a 4-year single-center experience. Methods: The clinical and imaging data of 751 patients (384 men; mean age 64 years, range 16-99) who had a TrapEase inferior vena cava (IVC) filter placed between January 1, 2001, and December 31, 2004, were reviewed retrospectively. More than a third of patients (297, 39.5%) presented with pulmonary embolism (PE), 188 (25.0%) had deep vein thrombosis (DVT), 40 (5.3%) had both PE and DVT, and the rest (226, 30.1%) had other symptoms. Indications for filter placement were contraindication to anticoagulation (461, 61.4%), complication of anticoagulation (42, 5.6%), failure of anticoagulation (39, 5.2%), and prophylaxis (209, 27.8%). Filters were placed in the infrarenal (n=738) or suprarenal (n=13) position through a femoral (n=729) or jugular vein (n=22) approach. Follow-up computed tomographic (CT) scans of the chest and abdomen were evaluated for recurrent PE and filter-related complications, respectively. Results: Three (0.4%) patients developed groin hematoma. During a mean 295-day clinical follow-up (range 1-1677), 55 (7.5%) patients developed symptoms of PE, and 1 (0.1%) death was attributed to PE. Chest CT performed for various clinical indications in 219 patients at a mean 192 days (range 1-1346) showed PE in 15 (6.8%) patients; 10 were symptomatic and 5 asymptomatic, but there were no fatalities. Follow-up abdominal CT (n=270) at a mean 189 days (range 1-1415) showed fracture of filter components in 8 (3.0%), thrombus within the filter in 68 (25.2%), thrombus extending beyond the filter in 4 (1.5%), near total caval occlusion in 2 (0.7%), and no cases of migration. Conclusion: The TrapEase vena cava filter is effective in the prevention of pulmonary embolism, with minimal complications.

Original languageEnglish (US)
Pages (from-to)365-372
Number of pages8
JournalJournal of Endovascular Therapy
Volume13
Issue number3
DOIs
StatePublished - Jun 2006

Fingerprint

Vena Cava Filters
Pulmonary Embolism
Venous Thrombosis
Thrombosis
Thorax
Venae Cavae
Groin
Jugular Veins
Thigh
Hematoma
Abdomen
Safety

Keywords

  • Complications
  • Deep venous thrombosis
  • Inferior vena cava
  • IVC filters
  • Pulmonary embolism
  • Venous thromboembolism

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Kalva, S. P., Wicky, S., Waltman, A. C., & Athanasoulis, C. A. (2006). TrapEase vena cava filter: Experience in 751 patients. Journal of Endovascular Therapy, 13(3), 365-372. https://doi.org/10.1583/05-1741.1

TrapEase vena cava filter : Experience in 751 patients. / Kalva, Sanjeeva P.; Wicky, Stephan; Waltman, Arthur C.; Athanasoulis, Christos A.

In: Journal of Endovascular Therapy, Vol. 13, No. 3, 06.2006, p. 365-372.

Research output: Contribution to journalArticle

Kalva, SP, Wicky, S, Waltman, AC & Athanasoulis, CA 2006, 'TrapEase vena cava filter: Experience in 751 patients', Journal of Endovascular Therapy, vol. 13, no. 3, pp. 365-372. https://doi.org/10.1583/05-1741.1
Kalva, Sanjeeva P. ; Wicky, Stephan ; Waltman, Arthur C. ; Athanasoulis, Christos A. / TrapEase vena cava filter : Experience in 751 patients. In: Journal of Endovascular Therapy. 2006 ; Vol. 13, No. 3. pp. 365-372.
@article{37dbd6b552ed478a952beef2cd2fa839,
title = "TrapEase vena cava filter: Experience in 751 patients",
abstract = "Purpose: To evaluate the clinical safety and efficacy of the TrapEase vena cava filter in a 4-year single-center experience. Methods: The clinical and imaging data of 751 patients (384 men; mean age 64 years, range 16-99) who had a TrapEase inferior vena cava (IVC) filter placed between January 1, 2001, and December 31, 2004, were reviewed retrospectively. More than a third of patients (297, 39.5{\%}) presented with pulmonary embolism (PE), 188 (25.0{\%}) had deep vein thrombosis (DVT), 40 (5.3{\%}) had both PE and DVT, and the rest (226, 30.1{\%}) had other symptoms. Indications for filter placement were contraindication to anticoagulation (461, 61.4{\%}), complication of anticoagulation (42, 5.6{\%}), failure of anticoagulation (39, 5.2{\%}), and prophylaxis (209, 27.8{\%}). Filters were placed in the infrarenal (n=738) or suprarenal (n=13) position through a femoral (n=729) or jugular vein (n=22) approach. Follow-up computed tomographic (CT) scans of the chest and abdomen were evaluated for recurrent PE and filter-related complications, respectively. Results: Three (0.4{\%}) patients developed groin hematoma. During a mean 295-day clinical follow-up (range 1-1677), 55 (7.5{\%}) patients developed symptoms of PE, and 1 (0.1{\%}) death was attributed to PE. Chest CT performed for various clinical indications in 219 patients at a mean 192 days (range 1-1346) showed PE in 15 (6.8{\%}) patients; 10 were symptomatic and 5 asymptomatic, but there were no fatalities. Follow-up abdominal CT (n=270) at a mean 189 days (range 1-1415) showed fracture of filter components in 8 (3.0{\%}), thrombus within the filter in 68 (25.2{\%}), thrombus extending beyond the filter in 4 (1.5{\%}), near total caval occlusion in 2 (0.7{\%}), and no cases of migration. Conclusion: The TrapEase vena cava filter is effective in the prevention of pulmonary embolism, with minimal complications.",
keywords = "Complications, Deep venous thrombosis, Inferior vena cava, IVC filters, Pulmonary embolism, Venous thromboembolism",
author = "Kalva, {Sanjeeva P.} and Stephan Wicky and Waltman, {Arthur C.} and Athanasoulis, {Christos A.}",
year = "2006",
month = "6",
doi = "10.1583/05-1741.1",
language = "English (US)",
volume = "13",
pages = "365--372",
journal = "Journal of Endovascular Therapy",
issn = "1526-6028",
publisher = "International Society of Endovascular Specialists",
number = "3",

}

TY - JOUR

T1 - TrapEase vena cava filter

T2 - Experience in 751 patients

AU - Kalva, Sanjeeva P.

AU - Wicky, Stephan

AU - Waltman, Arthur C.

AU - Athanasoulis, Christos A.

PY - 2006/6

Y1 - 2006/6

N2 - Purpose: To evaluate the clinical safety and efficacy of the TrapEase vena cava filter in a 4-year single-center experience. Methods: The clinical and imaging data of 751 patients (384 men; mean age 64 years, range 16-99) who had a TrapEase inferior vena cava (IVC) filter placed between January 1, 2001, and December 31, 2004, were reviewed retrospectively. More than a third of patients (297, 39.5%) presented with pulmonary embolism (PE), 188 (25.0%) had deep vein thrombosis (DVT), 40 (5.3%) had both PE and DVT, and the rest (226, 30.1%) had other symptoms. Indications for filter placement were contraindication to anticoagulation (461, 61.4%), complication of anticoagulation (42, 5.6%), failure of anticoagulation (39, 5.2%), and prophylaxis (209, 27.8%). Filters were placed in the infrarenal (n=738) or suprarenal (n=13) position through a femoral (n=729) or jugular vein (n=22) approach. Follow-up computed tomographic (CT) scans of the chest and abdomen were evaluated for recurrent PE and filter-related complications, respectively. Results: Three (0.4%) patients developed groin hematoma. During a mean 295-day clinical follow-up (range 1-1677), 55 (7.5%) patients developed symptoms of PE, and 1 (0.1%) death was attributed to PE. Chest CT performed for various clinical indications in 219 patients at a mean 192 days (range 1-1346) showed PE in 15 (6.8%) patients; 10 were symptomatic and 5 asymptomatic, but there were no fatalities. Follow-up abdominal CT (n=270) at a mean 189 days (range 1-1415) showed fracture of filter components in 8 (3.0%), thrombus within the filter in 68 (25.2%), thrombus extending beyond the filter in 4 (1.5%), near total caval occlusion in 2 (0.7%), and no cases of migration. Conclusion: The TrapEase vena cava filter is effective in the prevention of pulmonary embolism, with minimal complications.

AB - Purpose: To evaluate the clinical safety and efficacy of the TrapEase vena cava filter in a 4-year single-center experience. Methods: The clinical and imaging data of 751 patients (384 men; mean age 64 years, range 16-99) who had a TrapEase inferior vena cava (IVC) filter placed between January 1, 2001, and December 31, 2004, were reviewed retrospectively. More than a third of patients (297, 39.5%) presented with pulmonary embolism (PE), 188 (25.0%) had deep vein thrombosis (DVT), 40 (5.3%) had both PE and DVT, and the rest (226, 30.1%) had other symptoms. Indications for filter placement were contraindication to anticoagulation (461, 61.4%), complication of anticoagulation (42, 5.6%), failure of anticoagulation (39, 5.2%), and prophylaxis (209, 27.8%). Filters were placed in the infrarenal (n=738) or suprarenal (n=13) position through a femoral (n=729) or jugular vein (n=22) approach. Follow-up computed tomographic (CT) scans of the chest and abdomen were evaluated for recurrent PE and filter-related complications, respectively. Results: Three (0.4%) patients developed groin hematoma. During a mean 295-day clinical follow-up (range 1-1677), 55 (7.5%) patients developed symptoms of PE, and 1 (0.1%) death was attributed to PE. Chest CT performed for various clinical indications in 219 patients at a mean 192 days (range 1-1346) showed PE in 15 (6.8%) patients; 10 were symptomatic and 5 asymptomatic, but there were no fatalities. Follow-up abdominal CT (n=270) at a mean 189 days (range 1-1415) showed fracture of filter components in 8 (3.0%), thrombus within the filter in 68 (25.2%), thrombus extending beyond the filter in 4 (1.5%), near total caval occlusion in 2 (0.7%), and no cases of migration. Conclusion: The TrapEase vena cava filter is effective in the prevention of pulmonary embolism, with minimal complications.

KW - Complications

KW - Deep venous thrombosis

KW - Inferior vena cava

KW - IVC filters

KW - Pulmonary embolism

KW - Venous thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=33751176488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751176488&partnerID=8YFLogxK

U2 - 10.1583/05-1741.1

DO - 10.1583/05-1741.1

M3 - Article

C2 - 16784325

AN - SCOPUS:33751176488

VL - 13

SP - 365

EP - 372

JO - Journal of Endovascular Therapy

JF - Journal of Endovascular Therapy

SN - 1526-6028

IS - 3

ER -